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Abstract
Background: Kaposi’s sarcoma (KS) remains the most common malignancy among HIV-infected patients. Human herpesvirus type-
8 (HHV-8) is regarded as the infectious etiological agent of Kaposi’s sarcoma (KSHV). Diagnostic procedures associated with KSHV
are not routinely performed in HIV-infected subjects.
Objectives: The main objective of this study is to obtain information on KSHV epidemiology in Iranian HIV-infected individuals.
Patients andMethods: In the present cross-sectional study, 109 patients with established HIV infection, who visited a governmen-
tal and referral center for HIV screening in Tehran (Tehran west health center (TWHC)) between May 2014 and July 2015 were en-
rolled according to the convenience sample strategy. After peripheral blood collection, isolation of plasma and peripheral blood
mononuclear cell (PBMC) compartments, DNA extraction was performed. KSHV DNA was analyzed by nested polymerase chain re-
action (nested PCR) using primers from ORF-26 (virus minor capsid).
Results: Among all 109 HIV-infected patients, 67 (61.5%) were male, with an age range of 2 - 64 years (mean± standard deviation 35.8
± 13.3). KSHV DNA was found in PBMC and plasma samples of six (5.5%) and four (3.6%) patients, respectively.
Conclusions: This study revealed a considerable prevalence of KSHV DNA, during latent and lytic phases, among HIV-infected pa-
tients. Risk factors for KSHV infection acquisition and concurrent. 0+infection with HIV were also evaluated. Diagnosis of KSHV in
the group could be helpful for prognosis of Kaposi’s sarcoma and clinical management.
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1. Background
Kaposi’s sarcoma-associated herpes virus (KSHV), also
known as human herpes virus-8 (HHV-8) was first discov-
ered in 1994 (1). It is the infectious etiologic agent in all
forms of endothelial-origin tumor involving blood and
lymphatic vessels (Kaposi’s sarcoma) and is consistently as-
sociated with lymphoproliferative diseases such as body-
cavity-based lymphoma (BCBL) and multicentric Castle-
man’s disease (2-4). Although, Kaposi’s sarcoma (KS) re-
mains an uncommon cancer in human populations, KSHV
was affirmed as a class-one carcinogenic agent by the inter-
national agency for research on cancer (5).
The route of infection transmission is different. Saliva,
blood or blood products, sexual contact, and organ trans-
plantation may play an important role in KSHV transmis-
sion (6-8).
Following the occurrence of human immunodefi-
ciency virus (HIV) epidemics, the prevalence of KS grad-
ually increased. Hence, previous reports indicated that
immunosuppression, as in HIV-infected cases, was a sig-
nificant cofactor for KS development (9, 10). Nowadays,
KS remains the second most frequent malignancy in HIV-
infected patients worldwide (11).
The pathogenesis of KSHV depends on several risk fac-
tors, including risky sexual behaviors (12); intravenous
drug use (13); and immunocompromised patients such as
HIV-infected patients, especially in patients with low CD4
cell count and those who are not enrolled in highly active
antiretroviral therapy (HAART) (14). In the HAART era, the
incidence of KSHV-AIDS-related malignancy, including Ka-
posi’s sarcoma, seems to be dramatically decreased (15, 16).
Copyright © 2016, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial
4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the
original work is properly cited.
Hesamizadeh K et al.
2. Objectives
In Iran, there are few previous reports of KSHV among
HIV-infected patients. Given the above introduction, the
present study examines recent data on the molecular
prevalence of KSHV (HHV-8) among HIV-infected patients.
The findings may provide insights into significant future
public health impacts of KSHV in the context of HIV co-
infection in Iran.
3. Patients andMethods
3.1. Study Population
In the present cross-sectional investigation, blood sam-
ples were obtained from HIV-positive patients who at-
tended a governmental and referral center for HIV screen-
ing in Tehran [HIV screening and monitoring center of Iran
University of Medical Sciences, Tehran West health center
(TWHC)] between May 2014 and July 2015. All of the ad-
mitted patients were assessed for inclusion in the present
study, according to the convenience sampling strategy. In
total, 151 HIV-positive cases who were referred during the
study period were initially considered, of which 109 sub-
jects met the following inclusion criteria: 1) agreed to take
part in the current study, 2) Iranian nationality, 3) con-
firmed HIV infection, 4) negative for KS malignancy.
Of the 109 patients, 67 (61.5%) were male, and 8 (7.3%)
were children under ten years. The study protocol follows
the ethical principles of the Declaration of Helsinki in addi-
tion to relevant local regulations. The study protocols were
approved by the ethical committee of Iran University of
Medical Sciences (code and date of ethical approval: 24466.
IR.IUMS.REC.1394.), and written informed consent was ob-
tained for each subject. Questionnaires were filled out by
trained general practitioners who also interviewed the par-
ticipants. Personal demographic information included:
age, sex, homosexual or bisexual behavior, being an intra-
venous drug user, history of transfusion, hemophilia, and
thalassemia. The privacy for research participants was re-
spected in this study.
3.2. Collection and Preparation of the Samples
About 10 mL of peripheral blood was collected from
each patient into sterile EDTA-containing vacutainer tubes.
After separation of plasma from whole bloods by centrifu-
gation, aliquots were transferred to sterile microtubes,
and the samples were stored at -70°C until further molec-
ular analysis. The PBMCs of the samples were isolated by
a standard procedure of Ficoll-Hypaque (FH) gradient cen-
trifugation (Lymphoprep, Oslo, Norway), following an es-
tablished protocol (17). The PBMC pellet was washed more
than three times with phosphate-buffered saline (PBS) (pH
= 7.4 ± 0.2). The pellets were counted and then frozen at
-70°C until use. Plasma and PBMC samples taken from a pa-
tient with established Kaposi’s sarcoma, as well as a sam-
ple taken from a healthy blood donor, were used as positive
and negative controls, respectively.
3.3. Confirmation of HIV Infection and Determination of HIV Vi-
ral Loads
HIV infection was confirmed by Western blot kit (Di-
aplus, San Francisco, USA) according to the manufacturer’s
protocol. For determination of HIV viral loads, viral RNA
was extracted using a high pure viral nucleic acid kit
(Roche Diagnostics, Germany). HIV viral loads were deter-
mined using a COBAS TaqMan 48 Analyzer (Roche Diagnos-
tics, Germany) according to the manufacturer’s instruc-
tions.
3.4. CD4 Cell Count
Although, for HIV-infected individuals, CD4 cells count
by flow cytometry technique was performed in the Tehran
west health center (TWHC) at the same time as viral loads
were analyzed in Keyvan virology laboratory.
3.5. DNA Extraction
Specimens aliquots of 150 µL of plasma and approx-
imately 2 - 3 × 106 PBMCs were thawed, and then pel-
lets resuspended in 150 µL of phosphate-buffered saline
(PBS) were used for DNA extraction and processed by Nu-
cleoSpin® Dx Virus kit (Macherey-Nagel, Duren, Germany),
following the manufacturer’s instructions.
3.6. KSHV DNA Detection by Nested PCR
Detection of KSHV-DNA in plasma and PBMC speci-
mens was performed by nested polymerase chain reaction
(nested PCR) method.
A set of nested primers from the ORF26 coding region
(KSHV minor capsid, VP23) was used, including an outer
primer pair of 233-base span: forward primer HV1-1 (5’-AGC
CGA AAG GAT TCC ACC AT-3’), and reverse primer HV1-2 (5’-
TCC GTG TTG TCT ACG TCC AG-3’); and an inner primer pair
of 138-base span: forward primer HV1-3 (5’-TAT TCT GCA GCA
GCT GTT GG-3’), and reverse primer HV1-4 (5’-TCT ACG TCC
AGA CGA TAT GTG C-3’) (1, 18).
The first round PCR was performed in a 25 µL mixture
containing 2.5µL of each extracted sample, 1.5U of Taq DNA
polymerase, and 2.5 µL of 10× PCR buffer (Roche Diagnos-
tics, Germany), 10 pM of each outer primer, 200 µM mix
dNTPs, and 1.5 mM MgCl2 (CinnaGen, Alborz, Iran). Ampli-
fication was performed as follows: Initial denaturing for 5
minutes at 95°C and 35 cycles of 95°C for 40 seconds, 55°C
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for 45 seconds, and 72°C for 40 seconds, followed by a fi-
nal extension at 72°C for 8 minutes. After the first ampli-
fication, 2.5 µL of PCR product was added to a second PCR
amplification with the inner primer pair. For nested PCR,
the same procedure was performed as described for the
first PCR step. Amplification was performed for the second
step as follows: Initial denaturing for 5 minutes at 95°C,
and 35 cycles of 95°C for 35 seconds, 55°C for 40 seconds,
and 72°C for 35 seconds, followed by a final extension at
72°C for 8 minutes. PCR products (138-bp) of specimens
with positive and negative controls and DNA marker (ruler
100-bp) (Vivantis Technologies, Malaysia) were visualized
by 2% agarose gel electrophoresis with ethidium-bromide
staining (19). Positive results were verified by re-extracted
and nested PCR re-tested on numerous PBMC and plasma
new samples. Additionally, β-globin gene amplification
was performed on each sample using primers PCO3 and
PCO4 to ensure the accuracy of gene amplification (20, 21).
To prevent contamination of samples and PCR products in
each phase, standard circumspections on the basis of prin-
ciples and regulations were carefully followed.
3.7. Statistical Analysis
Statistical analysis was performed using SPSS software
(version 16; SPSS Inc., Chicago. IL, USA). Chi-squared or
Fisher’s exact tests were used to examine the associations
between categorical variables. To analyze to normality of
variables the Kolmogorov-Smirnov test was utilized. The
independent T-test and Mann-Whitney U-tests were ap-
plied to analyze the associations between continuous vari-
ables. Additionally, to confirm the reliability of results re-
garding the limited number of subjects, statistical anal-
yses were performed by bootstrap method analysis with
1000 pseudoreplicates. P values less than 0.05 were con-
sidered statistically significant.
4. Results
In the current study, molecular analysis for KSHV DNA
was conducted in 109 HIV-infected patients. Nested-PCR
was performed in paired PBMC and plasma samples. Over-
all, KSHV DNA was found in PBMC samples of six patients
(5.5%). Furthermore, KSHV DNA was detected only in four
their plasma samples (3.6%). As shown in Table 1, KSHV in-
fection was more prevalent in men; out of six positive re-
sults, 66.6% (4/6) patients were male and 33.3% (2/6) pa-
tients were female, with no significant differences. Obvi-
ous KSHV infection in different HIV-positive risk groups is
detailed in Table 2. The mean age of HIV-infected individ-
uals was 35.8 ± 13.3 years (range 2 - 64 years). The mean
± SD age of patients was 32.16 ± 12.13 in KSHV-positive
cases, which is similar to that of 35.93± 13.91 among KSHV-
negative patients (independent T-test, P = 0.518). Interest-
ingly, one of the six KSHV infected patients was a child un-
der ten years old.
Regarding the use of anti-retroviral therapy, out of 109
patients, 33% were receiving highly active anti-retroviral
therapy (HAART), some subjects had recently received
HAART, and some were receiving treatment at the time of
HIV diagnosis for months or years. Fisher’s exact test re-
vealed significant differences between positivity and neg-
ativity of KSHV infection, and in the use of HAART among
patients infected with HIV (P value = 0.042). The mean CD4
count was 377± 212 cells/µL (range 900 - 24 cells/µL). With
respect to CD4 cell count, there was no significant differ-
ence between KSHV-positive and -negative cases (indepen-
dent T-test, P = 0.18). In total, 24.8% of the patients had
CD4+ T-cell count > 500 cells/µL, 54.1% had counts between
200 cells/µL and 500 cells/µL, and 21.1% counts of < 200
cells/µL. As described previously, low CD4 count and not be-
ing on anti-retroviral therapy are the main risk factors for
Kaposi’s sarcoma development among KSHV-positive pa-
tients with AIDS (22). Accordingly, in 50% (3/6) of patients
positive for KSHV, the CD4 count was less than 200 cells/µL,
and 67% (4/6) were not under HAART treatment.
Viral hepatitis co-infection with HIV was reported in
57% with hepatitis C virus and 3.5% with hepatitis B
virus, respectively. None of the KSHV DNA-positive pa-
tients was co-infected with viral hepatitis, and also no-one
had proven history of AIDS-defining illnesses, including
Kaposi’s sarcoma (KS); however, clinical examination re-
vealed symptoms of skin lesions in some patients.
Among the HIV-infected patients, 42.2% (46/109) pa-
tients were male intravenous drug users (IVDU), and 24.7%
(27/109) of patients were women whose spouse had a his-
tory of intravenous drug use. Nevertheless, we observed
no significant difference between KSHV infection and be-
ing addictive. Among all patients, 38.3% (41/109) had a his-
tory of being in prison. Another major risk factor was ho-
mosexual and/or bisexual behavior among men: 10% of the
109 patients were homosexual and/or bisexual men with a
history of multi-unprotected sexual behavior. The preva-
lence of KSHV infection among intravenous drug users and
homosexual and/or bisexual subjects was the same in each
group, at 33.3% (2/6).
HIV viral loads ranged between very low values, close to
the assay detection limit, to more than 106 copies/mL. The
median viral loads were 9.54 E4 and 1.25 E3 in KSHV-positive
and KSHV-negative patients, respectively, and were not sta-
tistically significant (Mann-Whitney U-test, P = 0.245).
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Table 1. General Characteristics of Study Patients With Risk Factors: KSHV-Infected and Non-Infected Patientsa
Variable KSHV-Negative (n = 103) KSHV-Positive (n = 6) P Value
Gender 0.57
Male 63 (61.1) 4 (66.6)
Female 40 (38.9) 2 (33.3)
Marital status 0.52
Married 48 (46.6) 5 (83.3)
Single 37 (36) 1 (16.7)
Divorced 10 (9.7) -
Widow 8 (7.7) -
Level of education 0.24
Illiterate 66 (64.1) 5 (83.3)
High school graduate 29 (28.1) -
University graduate 8 (7.8) 1 (16.7)
History of addiction 43 (41.8) 1 (16.7) 0.51
Being in prison 38 (36.9) 3 (50.0) 0.42
Routes of HIV infection 0.43
IVDUs 44 (42.7) 2 (33.3)
Unprotected sex 9 (8.8) 2 (33.3)
IVDUs wife 26 (25.2) 1 (16.7)
Hemophilia and Thalassemia 4 (3.9) -
Mother to child “vertical” 9 (8.8) 1 (16.7)
Others 11 (10.6) -
Under treatmentwithHAART3 79 (76.7) 2 (33.3) 0.042
Abbreviations: HAART3, highly active anti-retroviral therapies; IVDUs, intravenous drug users; others, Through needle stick, dentistry services, unsafe hairdressing salon,
etc.
aValues are expressed as No. (%).
Table 2. KSHV Infection in Six Patients With Concurrent HIV Infection, on Detailed Demographical Data
Case Sex Age Marital Status Literacy HIV Acquisition HAART CD4 Count,µl-1 HIV Viral Load. Copies/mL
1 Female 31 Married Illiterate IVDU wife No 361 3900
2 Female 9 Single Illiterate Vertical Yes 412 1786
3 Male 33 Married University graduate Homosexual No 133 203337
4 Male 43 Married Illiterate IVDU Yes 644 1211
5 Male 39 Married Illiterate Homosexual No 24 319849
6 Male 38 Married Illiterate IVDU No 89 186927
5. Discussion
The present study assessed concurrent KSHV infection
in HIV-infected subjects, in addition to risk factors for KSHV
acquisition among HIV-infected subjects in Tehran. PBMC
and plasma samples from HIV-infected patients were an-
alyzed for molecular evaluation of KSHV. The results re-
vealed that the overall prevalence of KSHV infection among
HIV-positive patients was 5.5% (6/109). The findings sug-
gest that the rate of infection among HIV-infected patients
in Tehran, regardless of the presence of Kaposi’s sarcoma
(KS), is relatively high. Furthermore, as mentioned in pre-
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vious reports, HIV/AIDS remains a public health crisis in
Iran (23, 24), and KS is a common, life-threatening disease
among HIV-infected patients.
We also analyzed risk factors for HIV acquisition, and
found strong associations with intravenous drug users,
having been in prison, low educational level, high-risk sex-
ual behavior, and increased risk of transmission from in-
fected mothers to children.
In the study, most of patients were introduced as in-
fected patients with hepatitis C virus. In addition, HIV in-
fected patients are specific populations for HCV as same
as KSHV (25). Therefore, HCV patient’s finding is very im-
portant issue in the HIV settings (26). These are the first
data published on HIV-infected patients without Kaposi’s
sarcoma and KSHV co-infection molecular epidemiology
in Tehran. However, previous limited seroepidemiological
studies have been conducted among Iranian HIV-positive
patients; one reported 45.7% KSHV seroprevalence among
HIV-positive patients from Tehran, determined by IFT (27),
whereas another showed that the frequency of KSHV an-
tibodies among HIV-positive patients in Isfahan was only
18.2%, tested by ELISA (28). According to previous stud-
ies, among healthy global populations, KSHV infection is
less prevalent in northern Europe, North America, and in
most parts of Asia, but is more prevalent in most parts
of South America, Mediterranean regions, and certainly in
Sub-Saharan Africa (29). However, it is obvious that the epi-
demiological patterns in most parts of the world vary be-
tween HIV-infected populations. For example, in Turkey,
which neighbors Iran, the prevalence of KSHV DNA in HIV-
infected patients without KS was only 3.5% (30). Similar
studies in Hungary and northern Germany reported preva-
lence of 6.1% and 7.8%, respectively (21, 31).
In geographic areas where KSHV is comparatively com-
mon, KSHV prevalence displays the same pattern among
IVDUs and the general populations; nevertheless, it seems
that most KSHV-positive patients in the present study are
injecting drug users; furthermore, as expected, syringe
sharing, in addition to increasing the risk of hepatitis B
and C, is also a risk factor for KSHV infection (32). As in pre-
vious reports, most HIV-positive subjects were intravenous
drug users, therefore monitoring of the patients is very im-
portant for prevention of related disease (33-35).
This study showed that the incidence of infection can
also occur in other ways in addition to injection in Tehran:
KSHV might occur occasionally among individuals with
multiple sexual partners, particularly among those who
had sex with homosexual or bisexual men. It should
be mentioned that mother-to-child transmission during
child delivery or through breastfeeding is very unlikely to
occur; nevertheless, further investigation is required on
this issue (36-38).
PCR-based analysis of PBMC and plasma as two major
blood compartments showed latent and lytic infections in
this patient group, respectively. Four patients out of six
(67%) were positive for KSHV DNA in plasma. Detection of
DNA in plasma would be expected, mainly during viremia
phases.
KSHV is an uncommon infection in healthy popula-
tions, but has been seen in immunocompromised groups,
particularly in HIV-infected patients. In addition, accord-
ing to a study by Zong, KSHV is a highly host-adapted virus,
and infectivity of the virus only occurs under conditions
of immunosuppression (39). Therefore, the patients most
affected are those with suppressed immune system sup-
pressed, e.g., HIV-positive patients, especially those with
low CD4 count and who are not under treatment with
HAART. The main treatment for this infection is the use
of effective anti-retroviral therapy; therefore, Kaposi’s sar-
coma is comparatively rare in countries that have univer-
sal access to HAART. The results of this study demonstrate
a significant difference for HAART and KSHV infectivity (P
value = 0.042). Hence, it should be pointed out that HIV-
positive patients in Iran have convenient access to HAART,
which is perhaps a major reason why Kaposi’s sarcoma is
the rarest malignancy among HIV-infected subjects in Iran.
In comparison with the similar investigations in Iran
with some weaknesses including exclusively antibodies
evaluations, failure to molecular analysis and assessments
of mainly risk factors in HIV-positive patients (25, 26,
40), the current study was evaluated a multi risk factors
for KSHV infection in HIV-positive patients and evaluated
molecular epidemiology in paired PBMC and plasma spec-
imens of HIV-positive subjects and consequently investi-
gation of KSHV latent and lytic infections in the subjects
group provides valuable data on the epidemiology of KSHV
infection in Iran. However, this study has some limitations,
including its cross-sectional design, and the narrow sam-
ple size selected for this investigation, in addition to lack
of representation of the general population. It is necessary
to consider that access to HIV-positive patients in Iran is
simply not possible. Additionally, it should be mentioned
that the one of the main reasons for the statistical insignif-
icance of most positive and negative results between the
HIV-infected patients group was the small number of avail-
able patients.
5.1. Conclusion
The association of KSHV with addiction and unsafe
sexual behavior, found in our study, confirms that this
virus may be transmitted through multiple routes. The
main factors for the pathogenesis of the virus, particu-
larly progress toward Kaposi’s sarcoma in patients infected
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with HIV, are low CD4 count and lack of HAART. Accumulat-
ing evidence suggests that HAART plays a significant role
in protecting against KSHV-related malignancies; there-
fore, KSHV infection might have been resolved during suc-
cessful HIV therapy. In Iran, the diagnosis of KSHV is not
a routine procedure. According to data from the study,
the molecular prevalence of KSHV among HIV-infected pa-
tients in Tehran is relatively high, and therefore the screen-
ing of HIV cohorts for KSHV may be beneficial. Further re-
search will be necessary to define epidemiology, risk fac-
tors, and related malignances associated with KSHV infec-
tion in different high-risk groups in Iran.
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